Physiopathology, Diagnosis, and Treatment of Hypercortisolism

  • Rosario Pivonello
  • Davide Iacuaniello
  • Chiara Simeoli
  • Maria Cristina De Martino
  • Annamaria Colao
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Cushing’s syndrome (CS) is a serious clinical condition caused by endogenous or exogenous cortisol excess. Endogenous CS is a rare endocrine disorder caused by chronic excessive cortisol secretion. In approximately 80% of cases, endogenous CS is a consequence of an adrenocorticotropin (ACTH) hypersecretion (ACTH-dependent CS), generally due to a ACTH-secreting pituitary tumor (Cushing’s disease, CD, 70%), and, rarely, to an ACTH-secreting or corticotrophin releasing hormone (CRH)-secreting extra-pituitary tumor (Ectopic CS, ECS, 10%). In the remaining 20% of cases, CS is a direct consequence of autonomous cortisol overproduction by the adrenal glands (ACTH-independent CS), because of unilateral or bilateral adrenal diseases. This chapter reviews the physiopathology, the diagnostic algorithm required to establish the diagnosis and the main currently available treatments of CS.

Keywords

Cushing’s syndrome Cushing’s disease Ectopic Cushing’s syndrome Adrenal Cushing’s syndrome Cortisol Adrenocorticotropin Glucocorticoids 

References

  1. Alemanno G, Bergamini C, Prosperi P, Valeri A. Adrenalectomy: indications and options for treatment. Updat Surg. 2017;69(2):119–25.CrossRefGoogle Scholar
  2. Alexandraki K, Grossmann A. The ectopic ACTH syndrome. Rev Endocr Metab Disord. 2010;11:117–26.PubMedCrossRefGoogle Scholar
  3. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, et al. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94(8):2692–701.PubMedCrossRefGoogle Scholar
  4. Aniszewski JP, Young WF Jr, Thompson GB, Grant CS, et al. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg. 2001;25:934–40.PubMedCrossRefGoogle Scholar
  5. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593–602.PubMedCrossRefGoogle Scholar
  6. Assié G, Libé R, Espiard S, Rizk-Rabin M, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N Engl J Med. 2013;369:2105–14.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Assié G, Letouzé E, Fassnacht M, Jouinot A, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46(6):607–12.PubMedCrossRefGoogle Scholar
  8. Badrick E, Kirschbaum C, Kumari M. The relationship between smoking status and cortisol secretion. J Clin Endocrinol Metab. 2007;92(3):819–24.PubMedCrossRefGoogle Scholar
  9. Bano G, Mir F, Beharry N, et al. A novel medical treatment of Cushing’s due to ectopic ACTH in a patient with Neurofibromatosis type 1. Int J Endocrinol Metab. 2013;11(1):52–6.PubMedGoogle Scholar
  10. Barbot M, Albiger N, Ceccato F, Zilio M, et al. Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary. 2014;17(2):109–17.PubMedCrossRefGoogle Scholar
  11. Barroso-Sousa R, Lerario AM, Evangelista J, Papadia C, et al. Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome. Thyroid. 2014;24(6):1062–6.PubMedCrossRefGoogle Scholar
  12. Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, Dumont F, Dechamps F, Caramella C, Chanson P, Lanoy E, Borget I, Schlumberger M. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer. 2011;2(6):363–71.  https://doi.org/10.1007/s12672-011-0094-2. Review.PubMedCrossRefGoogle Scholar
  13. Baudry C, Coste J, Bou Khalil R, Silvera S, et al. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. Eur J Endocrinol. 2012;167(4):473–81.PubMedCrossRefGoogle Scholar
  14. Baudry C, Paepegaey AC, Groussin L. Reversal of Cushing’s syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med. 2013;369:584.PubMedCrossRefGoogle Scholar
  15. Benveniste RJ, King WA, Walsh J, Lee JS, et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg. 2005;102(6):1004–12.PubMedCrossRefGoogle Scholar
  16. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, Pentheroudakis G, ESMO Guidelines Working Group. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii131–8.Google Scholar
  17. Bertagna X, Bertagna C, Luton JP, Husson JM, et al. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab. 1984;59(1):25–8.PubMedCrossRefGoogle Scholar
  18. Bertagna X, Pivonello R, Fleseriu M, Zhang Y, et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014;99:1375–83.PubMedCrossRefGoogle Scholar
  19. Bigos ST, Somma M, Rasio E, Eastman RC, et al. Cushing’s disease: management by transsphenoidal pituitary microsurgery. J Clin Endocrinol Metab. 1980;50(2):348–54.PubMedCrossRefGoogle Scholar
  20. Biller BM, Alexander JM, Zervas NT, Hedley-Whyte ET, et al. Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing’s disease. J Clin Endocrinol Metab. 1992;75:1303–9.PubMedGoogle Scholar
  21. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115–22.PubMedCrossRefGoogle Scholar
  22. Cannavò S, Almoto B, Dall’Asta C, Corsello S, et al. Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur J Endocrinol. 2003;149(3):195–200.PubMedCrossRefGoogle Scholar
  23. Carballeira A, Fishman LM, Jacobi JD. Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: correlation of in vivo and in vitro studies. J Clin Endocrinol Metab. 1976;42(4): 687–95.PubMedCrossRefGoogle Scholar
  24. Carmichael JD, Fleseriu M. Mifepristone: is there a place in the treatment of Cushing’s disease? Endocrine. 2013;44(1):20–32.PubMedCrossRefGoogle Scholar
  25. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol. 2008;158(1):91–9.PubMedCrossRefGoogle Scholar
  26. Castinetti F, Fassnacht M, Johanssen S, Terzolo M, et al. Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol. 2009;160(6):1003–10.PubMedCrossRefGoogle Scholar
  27. Castinetti F, Brue T, Conte-Devolx B. The use of the glucocorticoid receptor antagonist mifepristone in Cushing’s syndrome. Curr Opin Endocrinol Diabetes Obes. 2012;19(4):295–9.PubMedCrossRefGoogle Scholar
  28. Castinetti F, Guignat L, Giraud P, Muller M, et al. Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab. 2014;99(5):1623–30.PubMedCrossRefGoogle Scholar
  29. Cavagnini F, Pecori Giraldi F. Epidemiology and follow-up of Cushing’s disease. Ann Endocrinol (Paris). 2001;62(2):168–72.Google Scholar
  30. Chart JJ, Sheppard H, Allen MJ, Bencze WL, et al. New amphenone analogs as adrenocortical inhibitors. Experientia. 1958;14(4):151–2.PubMedCrossRefGoogle Scholar
  31. Chow JT, Thompson GB, Grant CS, Farley DR, et al. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing’s syndrome: a review of the Mayo Clinic experience. Clin Endocrinol. 2008;68(4):513–9.CrossRefGoogle Scholar
  32. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery. 1997;40(2): 225–36; discussion 236–227.PubMedCrossRefGoogle Scholar
  33. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96:632–42.PubMedCrossRefGoogle Scholar
  34. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84:2664–72.PubMedGoogle Scholar
  35. Colao A, Ochoa AS, Auriemma RS, Faggiano A, et al. Pituitary carcinomas. Front Horm Res. 2010;38:94–108.PubMedCrossRefGoogle Scholar
  36. Colao A, Petersenn S, Newell-Price J, Findling JW, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366(10):914–24.PubMedCrossRefGoogle Scholar
  37. Colao A, De Block C, Gaztambide MS, Kumar S, et al. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17(2):180–6.PubMedCrossRefGoogle Scholar
  38. da Mota F, Murray C, Ezzat S. Overt immune dysfunction after Cushing’s syndrome remission: a consecutive case series and review of the literature. J Clin Endocrinol Metab 2011;96:E1670–74.PubMedCrossRefGoogle Scholar
  39. De Bruin C, Feelders RA, Lamberts SW, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s syndrome. Rev Endocr Metab Disord. 2009;10(2): 91–102.PubMedCrossRefGoogle Scholar
  40. De Leo M, Pivonello R, Auriemma RS, Cozzolino A, et al. Cardiovascular disease in Cushing’s syndrome: heart versus vasculature. Neuroendocrinology. 2010;92(Suppl 1):50–4.PubMedCrossRefGoogle Scholar
  41. De Martino MC, van Koetsveld PM, Feelders RA, Sprij-Mooij D, et al. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. Endocr Relat Cancer. 2012;19(3):351–64.PubMedCrossRefGoogle Scholar
  42. De Martino MC, Al Ghuzlan A, Aubert S, Assie G, et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J Clin Endocrinol Metab. 2013;98: 4080–8.PubMedCrossRefGoogle Scholar
  43. Di Somma C, Colao A, Pivonello R, et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing’s disease. Clin Endocrinol (Oxf). 1998;48:655–62.CrossRefGoogle Scholar
  44. Di Somma C, Pivonello R, Loche S, et al. Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood-onset and adulthood-onset disease. Clin Endocrinol (Oxf). 2002;56:153–58.CrossRefGoogle Scholar
  45. Di Somma C, Pivonello R, Loche S, et al. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clin Endocrinol (Oxf). 2003;58:302–08.Google Scholar
  46. Ding XF, Li HZ, Yan WG, Gao Y, et al. Role of adrenalectomy in recurrent Cushing’s disease. Chin Med J. 2010;123(13):1658–62.PubMedGoogle Scholar
  47. Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med. 1984;144(5):1069–70.PubMedCrossRefGoogle Scholar
  48. Dworakowska D, Grossman AB. The molecular pathogenesis of corticotroph tumours. Eur J Clin Investig. 2012;42(6):665–76.CrossRefGoogle Scholar
  49. Elamin MB, Murad MH, Mullan R, Erickson D, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93(5): 1553–62.PubMedCrossRefGoogle Scholar
  50. El-Farhan N, Rees DA, Evans C. Measuring cortisol in serum, urine and saliva – are our assays good enough? Ann Clin Biochem. 2017;54(3):308–22.PubMedCrossRefGoogle Scholar
  51. Else T, Kim AC, Sabolch A, Raymon VM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35: 282–326.PubMedCrossRefGoogle Scholar
  52. Ernest I, Ekman H. Adrenalectomy in Cushing’s disease. A long-term follow-up. Acta Endocrinol Suppl (Copenh). 1972;160:3–41.Google Scholar
  53. Estrada J, Boronat M, Mielgo M, Magallón R, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med. 1997;336(3): 172–7.PubMedCrossRefGoogle Scholar
  54. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiff ness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88:2527–33.PubMedCrossRefGoogle Scholar
  55. Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing’s syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology. 2010a;92(suppl 1):111–5.PubMedCrossRefGoogle Scholar
  56. Feelders RA, de Bruin C, Pereira AM, Romijn JA, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med. 2010b;362(19):1846–8.PubMedCrossRefGoogle Scholar
  57. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167:311–26.PubMedCrossRefGoogle Scholar
  58. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev. 1986;7(4):409–20.PubMedCrossRefGoogle Scholar
  59. Ferone D, Pivonello C, Vitale G, Zatelli MC, Colao A, Pivonello R. Molecular basis of pharmacological therapy in Cushing’s disease. Endocrine. 2014;46(2):181–98.  https://doi.org/10.1007/s12020-013-0098-5. Epub 2013 Nov 23. Review.PubMedCrossRefGoogle Scholar
  60. Findling JW, Raff H. DIAGNOSIS OF ENDOCRINE DISEASE: differentiation of pathologic/neoplastic hypercortisolism (Cushing’s syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing’s syndrome). Eur J Endocrinol. 2017;176(5):R205–16.PubMedCrossRefGoogle Scholar
  61. Fleseriu M, Biller BM, Findling JW, Molitch ME, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97(6):2039–49.PubMedCrossRefGoogle Scholar
  62. Fleseriu M, Molitch ME, Gross C, Schteingart DE, et al. A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone. Endocr Pract. 2013;19(2):313–26.PubMedCrossRefGoogle Scholar
  63. Fleseriu M, Pivonello R, Young J, Hamrahian AH, et al. Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease. Pituitary. 2016;19:138–48.PubMedCrossRefGoogle Scholar
  64. Friedman TC, Zuckerbraun E, Lee ML, Kabil MS, Shahinian H. Dynamic pituitary MRI has high sensitivity and specificity for the diagnosis of mild Cushing’s syndrome and should be part of the initial workup. Horm Metab Res. 2007;39(6):451–6.PubMedCrossRefGoogle Scholar
  65. Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, et al. ENETS consensus guidelines for high-grade Gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94.PubMedCrossRefGoogle Scholar
  66. Giordano R, Picu A, Marinazzo E, et al. Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of diff erent aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf). 2011;75:354–60.CrossRefGoogle Scholar
  67. Godbout A, Manavela M, Danilowicz K, Beauregard H, et al. Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol. 2010;163(5):709–16.PubMedCrossRefGoogle Scholar
  68. Gower DB. Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications. J Steroid Biochem. 1974;5:501–23.PubMedCrossRefGoogle Scholar
  69. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JO. Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012;23:278–82.PubMedCrossRefGoogle Scholar
  70. Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, et al. Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab. 2004;89(12):6348–57.PubMedCrossRefGoogle Scholar
  71. Hatipoglu E, Kepicoglu H, Rusen E, et al. Von Hippel Lindau disease with metastatic pancreatic neuroendocrine tumor causing ectopic Cushing’s syndrome. Neuro Endocrinol Lett. 2013;34(1):9–13.PubMedGoogle Scholar
  72. Henry RR, Ciaraldi TP, Armstrong D, Burke P, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8): 3446–53.PubMedCrossRefGoogle Scholar
  73. Hofmann BM, Hlavac M, Martinez R, Buchfelder M, et al. Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg. 2008;108(1):9–18.PubMedCrossRefGoogle Scholar
  74. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev. 1996;17(2):187–205.PubMedCrossRefGoogle Scholar
  75. Holthouse DJ, Robbins PD, Kahler R, Knuckey N, et al. Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol. 2001;12:329–41.PubMedCrossRefGoogle Scholar
  76. Hopkins RL, Leinung MC. Exogenous Cushing’s syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin N Am. 2005;34(2):371–84.CrossRefGoogle Scholar
  77. Igaz P, Tömböl Z, Szabó PM, Likó I, et al. Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Curr Med Chem. 2008;15(26):2734–47.PubMedCrossRefGoogle Scholar
  78. Ilias I, Torpy DJ, Pacak K, et al. Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the national institutes of health. J Clin Endocrinol Metab. 2005;90(8): 4955–62.PubMedCrossRefGoogle Scholar
  79. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of endocrinology on the pathophysiology of the hypothalamic-pituitary-adrenal Axis. J Clin Endocrinol Metab. 1999;84(2):440–8.PubMedGoogle Scholar
  80. Isidori AM, Kaltsas GA, Pozza C, Frajese V, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91:371–7.PubMedCrossRefGoogle Scholar
  81. Isidori AM, Sbardella E, Zatelli MC, Boschetti M, et al. Conventional and nuclear medicine imaging in ectopic Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab. 2015a;100(9):3231–44. Review.PubMedPubMedCentralCrossRefGoogle Scholar
  82. Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, Corsello SM, Pivonello R, ABC Study Group. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2015b;33(1):44–60.  https://doi.org/10.1097/HJH.0000000000000415. Review. PubMed PMID: 25415766; PubMed Central PMCID: PMC4342316.
  83. Jacobson L. Hypothalamic-pituitary-adrenocortical axis regulation. Endocrinol Metab Clin N Am. 2005;34(2):271–92, vii.CrossRefGoogle Scholar
  84. Jagannathan J, Smith R, DeVroom HL, Vortmeyer AO, et al. Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg. 2009;111:531–9.PubMedPubMedCentralCrossRefGoogle Scholar
  85. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, et al. Metyrapone in long-term management of Cushing’s disease. Br Med J. 1977;2(6081):215–7.PubMedPubMedCentralCrossRefGoogle Scholar
  86. Jimenez Reina L, Leal-Cerro A, Garcia J, Garcia-Luna PP, et al. In vitro effects of ketoconazole on corticotrope cell morphology and ACTH secretion of two pituitary adenomas removed from patients with Nelson’s syndrome. Acta Endocrinol. 1989;121(2):185–90.PubMedGoogle Scholar
  87. Jung-Testas I, Baulieu EE. Inhibition of glucocorticosteroid action in cultured L-929 mouse fibroblasts byRU486, a new anti-glucocorticosteroid of high affinity for the glucocorticosteroid receptor. Exp Cell Res. 1983;147(1):177–82.PubMedCrossRefGoogle Scholar
  88. Kamenicky P, Droumaquet C, Salenave S, Blanchard A, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab. 2011;96:2796–804.PubMedCrossRefGoogle Scholar
  89. Kawamata A, Iihara M, Okamoto T, Obara T. Bone mineral density before and after surgical cure of Cushing’s syndrome due to adrenocortical adenoma: prospective study. World J Sur. 2008;32(5):890–6.CrossRefGoogle Scholar
  90. Kelly WF, MacFarlane IA, Longson D, Davies D, et al. Cushing’s disease treated by total adrenalectomy: longterm observations of 43 patients. Q J Med. 1983;52(206):224–31.PubMedGoogle Scholar
  91. Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective, long-term study. Eur J Endocrinol. 2006;154:109–18.PubMedCrossRefGoogle Scholar
  92. Lacroix A, Tremblay J, Rousseau G, Bouvier M, et al. Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing’s syndrome. N Engl J Med. 1997;337:1429–34.PubMedCrossRefGoogle Scholar
  93. Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in luteinizing hormone-dependent Cushing’s syndrome. N Engl J Med. 1999;341:1577–81.PubMedCrossRefGoogle Scholar
  94. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386(9996): 913–27.PubMedCrossRefGoogle Scholar
  95. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, et al. Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients. J Clin Endocrinol Metab. 2013;98(3):1022–30.PubMedPubMedCentralCrossRefGoogle Scholar
  96. Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol. 2014;386(1–2):67–84.PubMedCrossRefGoogle Scholar
  97. Liddle GW, Island D, Lance EM, Harris AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 β hydroxylation. J Clin Endocrinol Metab. 1958;18(8):906–12.PubMedCrossRefGoogle Scholar
  98. Lila AR, Gopal RA, Acharya SV, George J, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract. 2010;16(6):968–76.PubMedCrossRefGoogle Scholar
  99. Liu H, Bravata DM, Cabaccan J, et al. Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol. 2005;63(6):642–9.CrossRefGoogle Scholar
  100. Loose DS, Kan PB, Hirst MA, Marcus RA, et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983;71(5):1495–9.PubMedPubMedCentralCrossRefGoogle Scholar
  101. Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, et al. Treatment of Cushing’s disease by O,p’DDD. Survey of 62 cases. N Engl J Med. 1979;300(9):459–64.PubMedCrossRefGoogle Scholar
  102. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med. 1988;109(6):487–93.PubMedCrossRefGoogle Scholar
  103. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004;61:768–77.CrossRefGoogle Scholar
  104. Margonis GA, Kim Y, Tran TB, et al. Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg. 2016;211(6):1106–13.PubMedCrossRefGoogle Scholar
  105. Martin NM, Dhillo WS, Banerjee A, Abdulali A, Jayasena CN, Donaldson M, Todd JF, Meeran K. Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab. 2006;1:2582–6.CrossRefGoogle Scholar
  106. Mericq MV, Cutler GB. High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab. 1998;83(2):682–4.PubMedCrossRefGoogle Scholar
  107. Miller BS, Ammori JB, Gauger PG, Broome JT, et al. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg. 2010;34:1380–5.PubMedCrossRefGoogle Scholar
  108. Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, Terzolo M. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing’s syndrome. Osteoporos Int. 2004;15:855–61.PubMedCrossRefGoogle Scholar
  109. Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, et al. Long-term follow-up results of postoperative radiation therapy for Cushing’s disease. J Neuro-Oncol. 2007;84(1):79–84.CrossRefGoogle Scholar
  110. Moncet D, Morando DJ, Pitoia F, Katz SB, et al. Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing’s syndrome. Medicina (B Aires). 2007;67(1): 26–31.Google Scholar
  111. Morgan FH, Laufgraben MJ. Mifepristone for management of Cushing’s syndrome. Pharmacotherapy. 2013;33(3):319–29.PubMedCrossRefGoogle Scholar
  112. Nagesser SK, van Seters AP, Kievit J, Hermans J, et al. Long-term results of total adrenalectomy for Cushing’s disease. World J Surg. 2000;24(1):108–13.PubMedCrossRefGoogle Scholar
  113. Nella AA, Lodish MB, Fox E, Balis FM, et al. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient. J Clin Endocrinol Metab. 2014;99(9):3055–9.PubMedPubMedCentralCrossRefGoogle Scholar
  114. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev. 1998;19(5):647–72.PubMedGoogle Scholar
  115. Newell-Price J, King P, Clark AJ. The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression. Mol Endocrinol. 2001;15:338–48.PubMedCrossRefGoogle Scholar
  116. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet. 2006;367: 1605–17.PubMedCrossRefGoogle Scholar
  117. Nieman LK, Biller BM, Findling JW, Newell-Price J, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40.PubMedPubMedCentralCrossRefGoogle Scholar
  118. Nieman LK, Biller BM, Findling JW, Murad MH, et al. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing’s syndrome. N Engl J Med. 1971;285(5):243–7.PubMedCrossRefGoogle Scholar
  120. Papadimitriou A, Priftis KN. Regulation of the hypothalamic-pituitary-adrenal axis. Neuroimmunomodulation. 2009;16(5):265–71.PubMedCrossRefGoogle Scholar
  121. Papanicolau DA, Yanovski JA, Cutler GB, et al. A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing states. J Clin Endocrinol Metab. 1998;83(4):1163–7.Google Scholar
  122. Park HS, Roman SA, Sosa JA. Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? Arch Surg. 2009;144:1060–7.PubMedCrossRefGoogle Scholar
  123. Patil CG, Prevedello DM, Lad SP, Vance ML, et al. Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008a;93(2):358–62.PubMedCrossRefGoogle Scholar
  124. Patil CG, Veeravagu A, Prevedello DM, Katznelson L, et al. Outcomes after repeat transsphenoidal surgery for recurrent Cushing’s disease. Neurosurgery. 2008b;63:266–70; discussion 270–271.PubMedCrossRefGoogle Scholar
  125. Pavel M, O’Toole D, Costa F, Capdevila J, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2): 172–85.PubMedCrossRefGoogle Scholar
  126. Pecori Giraldi F, Pivonello R, Ambrogio AG, De Martino MC, De Martin M, Scacchi M, Colao A, Toja PM, Lombardi G, Cavagnini F. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. Clin Endocrinol (Oxf). 2007;66(2):251–7. Erratum in: Clin Endocrinol (Oxf). 2007;67(3):477.Google Scholar
  127. Pecori Giraldi F, Cavallo LM, Tortora F, Pivonello R, Colao A, Cappabianca P, Mantero F, Altogether to Beat Cushing’s Syndrome Group. The role of inferior petrosal sinus sampling in ACTH-dependent Cushing’s syndrome: review and joint opinion statement by members of the Italian Society for Endocrinology, Italian Society for Neurosurgery, and Italian Society for Neuroradiology. Neurosurg Focus. 2015;38(2):E5.  https://doi.org/10.3171/2014.11.FOCUS14766. Review.
  128. Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA. Cardiac dysfunction is reversed upon successful treatment of Cushing’s syndrome. Eur J Endocrinol. 2010;162:331–40.PubMedCrossRefGoogle Scholar
  129. Perez-Rivas LG, Reincke M. Genetics of Cushing’s disease: an update. J Endocrinol Investig. 2016;39(1):29–35.CrossRefGoogle Scholar
  130. Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, et al. Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine. 2017;57(1):156–65.PubMedPubMedCentralCrossRefGoogle Scholar
  131. Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing’s syndrome. N Engl J Med. 2005a;352:2457–8.PubMedCrossRefGoogle Scholar
  132. Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin N Am. 2005b;34(2):327–39.CrossRefGoogle Scholar
  133. Pivonello R, Ferone D, de Herder WW, Faggiano A, et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab. 2007;92:65–9.PubMedCrossRefGoogle Scholar
  134. Pivonello R, De Martino MC, De Leo M, Lombardi G, et al. Cushing’s Syndrome. Endocrinol Metab Clin N Am. 2008;37(1):135–49.CrossRefGoogle Scholar
  135. Pivonello R, De Martino MC, Cappabianca P, De Leo M, et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223–30.PubMedCrossRefGoogle Scholar
  136. Pivonello R, De Leo M, Vitale P, Cozzolino A, et al. Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):77–81.PubMedCrossRefGoogle Scholar
  137. Pivonello R, Petersenn S, Newell-Price J, Findling JW, et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: results from a Phase III study. Clin Endocrinol. 2014;81(3):408–17.CrossRefGoogle Scholar
  138. Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing’s disease. Endocr Rev. 2015a;36(4):385–486.PubMedPubMedCentralCrossRefGoogle Scholar
  139. Pivonello R, Simeoli C, De Martino MC, Cozzolino A, et al. Neuropsychiatric disorders in Cushing’s syndrome. Front Neurosci. 2015b;9:129.PubMedPubMedCentralCrossRefGoogle Scholar
  140. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016a;4(7):611–29.PubMedCrossRefGoogle Scholar
  141. Pivonello R, De Martino MC, Iacuaniello D, Simeoli C, et al. Metabolic alterations and cardiovascular outcomes of cortisol excess. Front Horm Res. 2016b;46:54–65.PubMedCrossRefGoogle Scholar
  142. Pivonello R, De Martino MC, De Leo M, Simeoli C, et al. Cushing’s disease: the burden of illness. Endocrine. 2017;56(1):10–8.PubMedCrossRefGoogle Scholar
  143. Preumont V, Mermejo LM, Damoiseaux P, Lacroix A, et al. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing’s syndrome. Horm Metab Res. 2011;43:287–91.PubMedCrossRefGoogle Scholar
  144. Raff H, Sharma ST, Nieman LK. Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing’s syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol. 2014;4(2):739–69.PubMedPubMedCentralCrossRefGoogle Scholar
  145. Raffin-Sanson ML, de Keyzer Y, Bertagna X. Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions. Eur J Endocrinol. 2003;149: 79–90.PubMedCrossRefGoogle Scholar
  146. Reimondo G, Bovio S, Allasino B, De Francia S, Zaggia B, Micossi I, Termine A, De Martino F, Paccotti P, Di Carlo F, Angeli A, Terzolo M. The combined low-dose dexamethasone suppression corticotropinreleasing hormone test as a tool to rule out Cushing’s syndrome. Eur J Endocrinol. 2008;159(5):569–76.  https://doi.org/10.1530/EJE-08-0402. Epub 2008 Aug 19.PubMedCrossRefGoogle Scholar
  147. Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet. 2014;47:31–8.PubMedCrossRefGoogle Scholar
  148. Römer B, Lewicka S, Kopf D, Lederbogen F, et al. Cortisol metabolism in depressed patients and healthy controls. Neuroendocrinology. 2009;90(3):301–6.PubMedCrossRefGoogle Scholar
  149. Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab. 2000;85:42–47.PubMedGoogle Scholar
  150. Sautter AE, Cunningham SC, Kowdley GC. Laparoscopic adrenalectomy for adrenal cancer-a systematic review. Am Surg. 2016;82(5):420–6.PubMedGoogle Scholar
  151. Scangas GA, Laws ER Jr. Pituitary incidentalomas. Pituitary. 2014;17(5):486–91.PubMedCrossRefGoogle Scholar
  152. Schopohl J, Gu F, Rubens R, Van Gaal L, et al. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial. Pituitary. 2015;18(5):604–12.PubMedCrossRefGoogle Scholar
  153. Schteingart DE, Tsao HS, Taylor CI, McKenzie A, et al. Sustained remission of Cushing’s disease with mitotane and pituitary irradiation. Ann Intern Med. 1980;92(5):613–9.PubMedCrossRefGoogle Scholar
  154. Scillitani A, Mazziotti G, Di Somma C, Moretti S, Stigliano A, Pivonello R, Giustina A, Colao A, ABC Group. Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int. 2014;25(2):441–6.  https://doi.org/10.1007/s00198-013-2588-y. Epub 2013 Dec 6.PubMedCrossRefGoogle Scholar
  155. Scillitani A, Mazziotti G, Di Somma C, Moretti S, Stigliano A, Pivonello R, Giustina A, Colao A, ABC 2011. Cortisol and the muscle-bone axis: response to comments by Molfino et al. Osteoporos Int. 2015;26(5):1661–2.  https://doi.org/10.1007/s00198-014-2876-1. Epub 2015 Mar 6.PubMedCrossRefGoogle Scholar
  156. Sharma ST, Nieman LK. Prolonged remission after long-term treatment with steroidogenesis inhibitors in Cushing’s syndrome caused by ectopic ACTH secretion. Eur J Endocrinol. 2012;166:531–6.PubMedCrossRefGoogle Scholar
  157. Simeoli C, Auriemma RS, Tortora F, De Leo M, et al. The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine. 2015;50(3):725–40.PubMedCrossRefGoogle Scholar
  158. Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception. 2003;68(6):409–20.PubMedCrossRefGoogle Scholar
  159. Smith PW, Turza KC, Carter CO, Vance ML, et al. Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J Am Coll Surg. 2009;208(6):1059–64.PubMedCrossRefGoogle Scholar
  160. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987;317(13):812–8.PubMedCrossRefGoogle Scholar
  161. Sonino N, Boscaro M, Paoletta A, Mantero F, et al. Ketoconazole treatment in Cushing’s syndrome: experience in 34 patients. Clin Endocrinol. 1991;35(4):347–52.CrossRefGoogle Scholar
  162. Takagi J, Otake K, Morishita M, et al. Multiple endocrine neoplasia type I and Cushing’s syndrome due to an aggressive ACTH producing thymic carcinoid. Intern Med. 2006;45(2):81–6.PubMedCrossRefGoogle Scholar
  163. Tauchmanovà L, Pivonello R, Di Somma C, et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab. 2006;91:1779–84.PubMedCrossRefGoogle Scholar
  164. Tauchmanovà L, Pivonello R, De Martino MC, et al. Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. Eur J Endocrinol. 2007;157:359–66.PubMedCrossRefGoogle Scholar
  165. Terzolo M, Stigliano A, Chiodini I, Loli P, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851–70.PubMedCrossRefGoogle Scholar
  166. Thorén M, Adamson U, Sjöberg HE. Aminoglutethimide and metyrapone in the management of Cushing’s syndrome. Acta Endocrinol. 1985;109(4):451–7.PubMedGoogle Scholar
  167. Tirabassi G, Faloia E, Papa R, Furlani G, et al. Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J Clin Endocrinol Metab. 2010;95(3):1115–22.PubMedCrossRefGoogle Scholar
  168. Trementino L, Michetti G, Angeletti A, Marcelli G, et al. A single-center 10-year experience with Pasireotide in Cushing’s disease: Patients’ characteristics and outcome. Horm Metab Res. 2016;48(5):290–8.PubMedCrossRefGoogle Scholar
  169. Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, et al. Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 1994;30(3): 557–65.PubMedCrossRefGoogle Scholar
  170. Valassi E, Crespo I, Gich I, Rodríguez J, et al. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol. 2012;77(5):735–42.CrossRefGoogle Scholar
  171. Valerio L, Pieruzzi L, Giani C, Agate L, et al. Targeted therapy in thyroid cancer: state of the art. Clin Oncol (R Coll Radiol). 2017;29(5):316–24.CrossRefGoogle Scholar
  172. van den Bosch OF, Stades AM, Zelissen PM. Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing’s disease. Clin Endocrinol. 2014;80(2):184–90.CrossRefGoogle Scholar
  173. van der Pas R, de Herder WW, Hofl LJ, Feelders RA. New developments in the medical treatment of Cushing’s syndrome. Endocr Relat Cancer. 2012;19:R205–23.PubMedCrossRefGoogle Scholar
  174. van Uum SH, Lenders JW, Hermus AR. Cortisol, 11β-hydroxysteroid dehydrogenases, and hypertension. Semin Vasc Med. 2004;4(2):121–8.PubMedCrossRefGoogle Scholar
  175. Verhelst JA, Trainer PJ, Howlett TA, Perry L, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol. 1991;35(2): 169–78.CrossRefGoogle Scholar
  176. Vilar O, Tullner WW. Effects of o,p’ DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology. 1959;65(1):80–6.PubMedCrossRefGoogle Scholar
  177. Vilar L, Freitas MC, Faria M, et al. Pitfalls in the diagnosis of Cushing’s syndrome. Arq Bras Endocrinol Metabol. 2007;51(8):1207–16.PubMedCrossRefGoogle Scholar
  178. Vilar L, Naves LA, Azevedo MF, Arruda MJ, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary. 2010;13(2):123–9.PubMedCrossRefGoogle Scholar
  179. Vitale G, Tortora F, Baldelli R, Cocchiara F, et al. Pituitary magnetic resonance imaging in Cushing’s disease. Endocrine. 2017;55(3):691–6.PubMedCrossRefGoogle Scholar
  180. von Werder K, Muller OA, Stalla GK. Somatostatin analogs in ectopic corticotropin production. Metabolism. 1996;45(Suppl 1):129–31.CrossRefGoogle Scholar
  181. Wagenmakers MA, Boogaarts HD, Roerink SH, Timmers HJ, et al. Endoscopic transsphenoidal pituitary surgery: a good and safe primary treatment option for Cushing’s disease, even in case of macroadenomas or invasive adenomas. Eur J Endocrinol. 2013;169(3):329–37.PubMedCrossRefGoogle Scholar
  182. Welbourn RB. Survival and causes of death after adrenalectomy for Cushing’s disease. Surgery. 1985;97(1):16–20.PubMedGoogle Scholar
  183. Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B. Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome – recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem. 1997;34(Pt 3):222–9.PubMedCrossRefGoogle Scholar
  184. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. JAMA. 1993;269(17):2232–8.PubMedCrossRefGoogle Scholar
  185. Ye L, Li X, Kong X, Wang W, et al. Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids. J Endocrinol. 2005;185:337–43.PubMedCrossRefGoogle Scholar
  186. Young RB, Bryson MJ, Sweat ML, Street JC. Complexing of DDT and o,p’DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem. 1973;4(6):585–91.PubMedCrossRefGoogle Scholar
  187. Young WF Jr, Scheithauer BW, Gharib H, Laws ER Jr, et al. Cushing’s syndrome due to primary multinodular corticotrope hyperplasia. Mayo Clin Proc. 1988;63:256–62.PubMedCrossRefGoogle Scholar
  188. Zeiger MA, Pass HI, Doppman JD, Nieman LK, et al. Surgical strategy in the management of non-small cell ectopic adrenocorticotropic hormone syndrome. Surgery. 1992;112:994–1000; discussion 1000–1001.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Rosario Pivonello
    • 1
  • Davide Iacuaniello
    • 1
  • Chiara Simeoli
    • 1
  • Maria Cristina De Martino
    • 1
  • Annamaria Colao
    • 1
  1. 1.Dipartimento di Medicina Clinica e Chirurgia, Sezione di EndocrinologiaUniversità Federico II di NapoliNaplesItaly

Personalised recommendations